We are live on
!
Find out more
Adage Capital Partners Portfolio holdings
AUM
$71.3B
1-Year Est. Return
56.8%
This Fund
S&P 500
This Quarter
Est. Return
+24.89%
1 Year Est. Return
+56.8%
3 Year Est. Return
+170.28%
5 Year Est. Return
+249.16%
10 Year Est. Return
+1,007.9%
AUM
$71.3B
AUM Growth
+$6.48B
(+10%)
Cap. Flow
-$2.43B
Cap. Flow
% of AUM
-3.41%
Top 10 Holdings %
Top 10 Hldgs %
29.48%
Holding
1,130
New
174
Increased
291
Reduced
392
Closed
128
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Devon Energy
DVN
|
+$353M |
| 2 |
Marvell Technology
MRVL
|
+$150M |
| 3 |
Spyre Therapeutics
SYRE
|
+$126M |
| 4 |
BridgeBio Pharma
BBIO
|
+$116M |
| 5 |
Dover
DOV
|
+$110M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Revolution Medicines
RVMD
|
+$713M |
| 2 |
CNTA
Centessa Pharmaceuticals
CNTA
|
+$355M |
| 3 |
CTRA
Coterra Energy
CTRA
|
+$289M |
| 4 |
Royalty Pharma
RPRX
|
+$259M |
| 5 |
Eli Lilly
LLY
|
+$236M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 32.29% |
| 2 | Healthcare | 14.03% |
| 3 | Financials | 12.39% |
| 4 | Industrials | 8.94% |
| 5 | Communication Services | 8.58% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
PSKY
851
Paramount Skydance Corp
PSKY
$11.5B
| $2.77M | ﹤0.01% |
281,171
+3,900
| +1% | +$41K |
|
|
LONA
852
LeonaBio Inc
LONA
$66.3M
| $2.76M | ﹤0.01% |
+300,000
| New | +$2.79M |
|
853
Amcor
AMCR
$19.9B
| $2.69M | ﹤0.01% |
62,098
-300,100
| -83% | -$11.9M |
|
854
Vertical Aerospace
EVTL
$99.4M
| $2.61M | ﹤0.01% |
1,500,000
| – | – |
|
855
Compass Therapeutics
CMPX
$393M
| $2.6M | ﹤0.01% |
1,186,500
-7,300,000
| -86% | -$21.6M |
|
856
Fulton Financial
FULT
$4.47B
| $2.58M | ﹤0.01% |
+106,624
| New | +$2.34M |
|
|
CEPV
857
Cantor Equity Partners V
CEPV
$330M
| $2.58M | ﹤0.01% |
250,000
| – | – |
|
|
KMTS
858
Kestra Medical Technologies
KMTS
$1.41B
| $2.54M | ﹤0.01% |
+100,000
| New | +$2.09M |
|
859
Macerich
MAC
$6.53B
| $2.52M | ﹤0.01% |
100,000
-5,000
| -5% | -$112K |
|
860
Piper Sandler
PIPR
$5.44B
| $2.46M | ﹤0.01% |
+34,006
| New | +$2.76M |
|
861
Forward Air
FWRD
$553M
| $2.39M | ﹤0.01% |
177,069
-100,000
| -36% | -$1.49M |
|
862
Adicet Bio
ACET
$89.3M
| $2.37M | ﹤0.01% |
274,375
| – | – |
|
|
MRSH
863
Marsh
MRSH
$84.4B
| $2.36M | ﹤0.01% |
14,160
-339,501
| -96% | -$56.8M |
|
864
Surrozen
SRZN
$235M
| $2.3M | ﹤0.01% |
88,653
| – | – |
|
865
SCYNEXIS
SCYX
$48.9M
| $2.21M | ﹤0.01% |
+543,478
| New | +$3.37M |
|
866
ProMIS Neurosciences
PMN
$129M
| $2.16M | ﹤0.01% |
164,275
+25,000
| +18% | +$271K |
|
867
Immunic
IMUX
$166M
| $2.15M | ﹤0.01% |
139,860
| – | – |
|
868
Rayonier
RYN
$6.09B
| $2.13M | ﹤0.01% |
+100,000
| New | +$2.09M |
|
869
Saic
SAIC
$5.29B
| $2.07M | ﹤0.01% |
+18,765
| New | +$1.9M |
|
870
Henry Schein
HSIC
$9.8B
| $2.03M | ﹤0.01% |
24,300
-18,000
| -43% | -$1.38M |
|
|
NBP
871
NovaBridge Biosciences American Depositary Shares
NBP
$197M
| $1.95M | ﹤0.01% |
1,000,000
| – | – |
|
872
Cogent Biosciences
COGT
$5.93B
| $1.94M | ﹤0.01% |
50,000
| – | – |
|
873
Hormel Foods
HRL
$11.5B
| $1.93M | ﹤0.01% |
77,946
-12,200
| -14% | -$271K |
|
874
Aveanna Healthcare
AVAH
$3.06B
| $1.92M | ﹤0.01% |
223,802
-753,134
| -77% | -$5.31M |
|
|
NUAI
875
New Era Energy & Digital Inc
NUAI
$691M
| $1.91M | ﹤0.01% |
300,000
-1,200,000
| -80% | -$5.83M |
|
Similar funds
Adage Capital Partners's Q2 2026 Portfolio in Review
As of Q2 2026, Adage Capital Partners held 1,130 positions worth $71.3B, up 10% from $64.8B the previous quarter. Its ten largest holdings account for 29% of the portfolio.
Adage Capital Partners withdrew a net $2.43B in Q2 2026, closing 128 positions and reducing 392 holdings. Its most notable exit was Centessa Pharmaceuticals, an estimated $355M position sold in full.
By sector, the portfolio is most concentrated in Technology at 32% of assets, up from 27% a quarter earlier, followed by Healthcare and Financials.
Against the trend, Adage Capital Partners opened a new position in Marvell Technology worth $222M.
- Adage Capital Partners's largest Q2 2026 buy was Marvell Technology: 745,800 shares worth $222M.
- Adage Capital Partners added most to Devon Energy in Q2 2026, an estimated $353M increase.
- Adage Capital Partners's biggest Q2 2026 reduction was Revolution Medicines, cutting an estimated $713M.
- Adage Capital Partners fully exited Centessa Pharmaceuticals in Q2 2026, selling an estimated $355M.
- Adage Capital Partners's ten largest holdings make up 29% of its $71.3B portfolio in Q2 2026.
- Adage Capital Partners opened 174 new positions and closed 128 in Q2 2026.
- Adage Capital Partners's portfolio value rose 10% quarter-over-quarter to $71.3B.
Based on Adage Capital Partners's 13F filing for Q2 2026, filed 14 Aug 2026.